Efficacy and Safety of NP-2007 on Skin Health

A 12-week, Randomized, Double-Blind, Placebo-Controlled Human Clinical Study to Evaluate the Efficacy and Safety of Small-Molecular-Weight Deer Antler Collagen (NP-2007) for Improving Skin Health

The objective of this study is to evaluate the efficacy and safety of Small-molecular-weight deer antler collagen (NP-2007) on skin health, including skin hydration, transepidermal water loss (TEWL), elasticity, and eye wrinkles.

Study Overview

• Status: Completed
• Conditions: Skin Aging, Dry Skin
• Intervention / Treatment: Dietary supplement: NP-2007; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 84
• Phase: Not Applicable

Contacts and Locations

Study Locations

• South Korea
  • Seoul, South Korea
    • Corederm Skin Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Healthy females between 35 and 65 years of age
2. Subjects with dry skin (Skin capacitance ≤ 49 units measured by Corneometer® CM 825)
3. Subjects with eye wrinkles (grade 3 or higher based on visual assessment scale)
4. Subjects who voluntarily signed the informed consent form after receiving a full explanation of the study
5. Subjects who are available for follow-up visits at scheduled times throughout the study period

Exclusion Criteria:

• 1) Subjects with skin diseases (atopic dermatitis, psoriasis, etc.) in the test area

  2) Subjects who have used skin-related medications (steroids, etc.) within 1 month

  3) Subjects with a history of hypersensitivity to the test ingredients or severe food allergies

  4) Pregnant or lactating women, or those planning to become pregnant

  5) Subjects who have participated in other clinical trials within the past 3 months

  6) Any other conditions that the investigator deems unsuitable for participation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NP-2007; 500mg/day, once a day, take 2 tablets with water.	Dietary supplement: NP-2007; 500mg/day, once a day, take 2 tablets with water.
Placebo Comparator: Placebo; Take 2 tablets (matching NP-2007) once a day with water.	Dietary supplement: Placebo; Take 2 tablets (matching NP-2007) once a day with water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from Baseline in Skin Hydration at 12 weeks	Measured using Corneometer® CM 825. The unit of measure is arbitrary units (AU) ranging from 0 to 120. Higher scores indicate improved skin moisture.	Baseline, 6 weeks, 12 weeks
Change from Baseline in Transepidermal Water Loss (TEWL) at 12 Weeks	Measured using Tewameter® TM 300. The unit of measure is g/m²/h. Lower values indicate improved skin barrier function.	Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Scaling at 12 Weeks	Evaluated using D-Squame® and image analysis. Higher values indicate more scaling (worse), lower values indicate improvement.	Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Roughness at 12 Weeks	Measured using Visiometer® SV 700. Assesses the texture of the skin surface. Lower values indicate smoother skin.	Baseline, 6 weeks, 12 weeks
Change from Baseline in Eye Wrinkles (Ra) at 12 Weeks	Quantitative analysis of eye wrinkles (crow's feet) using Visiometer® SV 700. Ra represents the average roughness in millimeters (mm). Lower values indicate improved wrinkle depth.	Baseline, 6 weeks, 12 weeks
Change from Baseline in Skin Elasticity (R2) at 12 Weeks	Measured using Cutometer® MPA 580. R2 represents gross elasticity (0 to 1 scale). Higher values indicate better skin elasticity.	Baseline, 6 weeks, 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator's Visual Assessment Grade for Eye Wrinkles	Baseline, 6 weeks, 12 weeks Clinical grading of eye wrinkle severity by a dermatologist using a visual analog scale. The scale ranges from 0 to 9, where 0 indicates 'None' (no wrinkles) and 9 indicates 'Very Severe' wrinkles. A decrease in the score (lower values) represents a better outcome (improvement in wrinkles).	Clinical grading of eye wrinkle severity by a dermatologist. The grade is based on a visual scale from 0 to 9 (0 = None, 9 = Very Severe). Lower grades indicate clinical improvement in wrinkle severity.
Participant Subjective Questionnaire Assessment for Skin Improvement	6 weeks, 12 weeks Participants' self-assessment of skin improvement using a 5-point Likert scale. The scale ranges from 1 to 5, where 1 indicates 'Very Dissatisfied' and 5 indicates 'Very Satisfied'. A higher score represents a better outcome (higher satisfaction and perceived efficacy).	Participants assess skin improvement and satisfaction through a self-report questionnaire using a 5-point Likert scale (1 = Very Dissatisfied, 5 = Very Satisfied). Higher scores indicate greater satisfaction with the product's efficacy.

Collaborators and Investigators

• Sponsor: Hanpoong Nature Pharm Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): April 4, 2022
• Primary Completion (Actual): July 15, 2022
• Study Completion (Actual): September 30, 2022

Study Registration Dates

• First Submitted: March 13, 2026
• First Submitted That Met QC Criteria: March 17, 2026
• First Posted (Actual): March 20, 2026

Study Record Updates

• Last Update Posted (Actual): March 20, 2026
• Last Update Submitted That Met QC Criteria: March 17, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: NP2007_HPN

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No